Blocking of the TNF-α, the NF-κB pathways have been a focus of the anti-psoriasis treatments as it leads to the reduction in the inflammasome activation and downregulation of the cytokine such as IL-1β (Goldminz et al., 2013; Moorchung et al., 2014). The gene discussed is NFKB1; the disease is psoriasis.